A specific microbial metabolite in the gut microbiome that helps regulate brain activity is linked to anxiety, a new study in ...

The incidence of gastrointestinal adverse reactions was higher in the Rezdiffra arms compared with placebo. Diarrhea and nausea typically began early upon treatment initiation and were mild to ...

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

Broccoli sprout extract (BSE) modestly lowered fasting blood glucose in prediabetes, but its effectiveness depended on gut ...

Longevity is increasing worldwide, and Dr Ray O’Connor takes a look at some of the most recent clinical studies on the subject of gerontology ...

A new Cochrane review showed SSRIs and SNRIs outperform placebo for GAD with similar dropout rates, but questions remain ...

Crohn’s disease isn’t just about digestion. From joint pain to vision issues, its hidden symptoms affect the body in unexpected ways.

Studies suggest collagen supplementation may help improve conditions such as osteoarthritis, osteoporosis, sarcopenia, ...

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh ...